JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

The pediatric metabolic syndrome.

Minerva Medica 2008 June
The metabolic syndrome is a frequent subject of attention, discussion, and debate in medical research, because of its linkages to the growing problem of obesity on the one hand and both diabetes mellitus and cardiovascular disease on the other. It is also the grounds for contention, as respected researchers disagree on its definition and even on its validity as a construct. This clustering of obesity, dyslipidemia, elevated blood pressure, impaired glucose metabolism, and acute phase reactants can be seen in children as well as in adults. There are at least five definitions of adult metabolic syndrome promulgated by different societies and organizations, and as many as 40 different definitions of the syndrome have been used in pediatric studies. In 2007, the International Diabetes Federation published a definition of pediatric metabolic syndrome; whether it unifies the field remains to be seen. In addition, long term cohort studies have furnished data showing that clusters of the factors used to identify metabolic syndrome do predict the presence of type 2 diabetes and cardiovascular disease defined as myocardial infarction, stroke, coronary artery bypass graft, and/or positive angiogram. In addition, longitudinal studies have demonstrated compromised vascular function in young adults with metabolic syndrome, variously defined, as children and adolescents. This review discusses the background and development of the concept of a metabolic syndrome, the inter-relationships among its constitutive elements, the debates surrounding the uses of the concept and possible treatment avenues.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app